Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Altimmune (ALT – Research Report) received a Hold rating and price target from William Blair analyst Andy Hsieh today. The company’s shares ...

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...

Ratings for Altimmune (NASDAQ:ALT) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...

NASDAQ:ALT opened at $6.65 on Friday. Altimmune has a 1-year low of $5.28 and a 1-year high of $14.05. The business’s 50-day moving average price is $6.85 and its two-hundred day moving average ...

Good day, ladies and gentlemen, and welcome to Altimmune fourth quarter and full year 2024 financial results conference call. As a reminder, this call is being recorded. (Operator Instructions) I ...

Good day, ladies and gentlemen, and welcome to Altimmune Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, this call is being recorded. After the speakers ...

Altimmune, Inc. (NASDAQ:ALT – Free Report) – Stock analysts at B. Riley increased their FY2025 earnings estimates for Altimmune in a research note issued on Friday, February 28th. B.

Earnings per share (EPS) was mostly in line with analyst estimates. Looking ahead, revenue is forecast to grow 66% p.a. on ...

Altimmune Inc (NASDAQ:ALT) has completed enrollment in its phase 2b trial for pemvidutide in MASH, with top-line data expected in Q2 2025. The company has submitted INDs for pemvidutide in two ...

Altimmune Inc (ALT) reports a strong cash position and promising trial developments, despite increased expenses and ...